Therapeutic directions for Parkinson's disease

about

Protection of dopaminergic cells by urate requires its accumulation in astrocytes

P2860

Q36223240-91F97412-AE27-4B38-9B83-1FFF9CA90401

P2860

Therapeutic directions for Parkinson's disease

Item

http://www.wikidata.org/entity/Q28743874

description

2010 nî lūn-bûn

@nan

2010 թուականին հրատարակուած գիտական յօդուած

@hyw

2010 թվականին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Therapeutic directions for Parkinson's disease

@ast

Therapeutic directions for Parkinson's disease

@en

Therapeutic directions for Parkinson's disease

@nl

type

Item

label

Therapeutic directions for Parkinson's disease

@ast

Therapeutic directions for Parkinson's disease

@en

Therapeutic directions for Parkinson's disease

@nl

prefLabel

Therapeutic directions for Parkinson's disease

@ast

Therapeutic directions for Parkinson's disease

@en

Therapeutic directions for Parkinson's disease

@nl

P1476

Therapeutic directions for Parkinson's disease

@en

P2093

Ira Shoulson

http://www.w3.org/2001/XMLSchema#string

P2860

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Plasma urate and risk of Parkinson's disease.

Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease

Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.

P304

S152-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.22790

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

25 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41579886

http://www.w3.org/2001/XMLSchema#string

P698

20187232

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3110693

http://www.w3.org/2001/XMLSchema#string

Therapeutic directions for Parkinson's disease

about

P2860

P2860

Therapeutic directions for Parkinson's disease

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932